These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 19875499)

  • 1. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
    Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH
    Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model.
    Lundquist P; Lööf J; Fagerholm U; Sjögren I; Johansson J; Briem S; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):459-68. PubMed ID: 24396143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.
    Riley RJ; McGinnity DF; Austin RP
    Drug Metab Dispos; 2005 Sep; 33(9):1304-11. PubMed ID: 15932954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jun; 59(6):803-28. PubMed ID: 17637173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds.
    Huang L; Chen A; Roberts J; Janosky B; Be X; Berry L; Lin MH
    Xenobiotica; 2012 Sep; 42(9):830-40. PubMed ID: 22439758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs.
    Poulin P
    J Pharm Sci; 2013 Jul; 102(7):2085-95. PubMed ID: 23613473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
    Nishimuta H; Sato K; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds.
    Sohlenius-Sternbeck AK; Afzelius L; Prusis P; Neelissen J; Hoogstraate J; Johansson J; Floby E; Bengtsson A; Gissberg O; Sternbeck J; Petersson C
    Xenobiotica; 2010 Sep; 40(9):637-49. PubMed ID: 20624033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
    Miller DW; Hinton M; Chen F
    Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
    Ito K; Houston JB
    Pharm Res; 2004 May; 21(5):785-92. PubMed ID: 15180335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance.
    Deshmukh SV; Harsch A
    J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo.
    Soars MG; Grime K; Sproston JL; Webborn PJ; Riley RJ
    Drug Metab Dispos; 2007 Jun; 35(6):859-65. PubMed ID: 17344337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.
    Brown HS; Griffin M; Houston JB
    Drug Metab Dispos; 2007 Feb; 35(2):293-301. PubMed ID: 17132764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.